Sanctuary Advisors LLC Takes Position in Krystal Biotech, Inc. $KRYS

Sanctuary Advisors LLC bought a new position in Krystal Biotech, Inc. (NASDAQ:KRYS) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 2,692 shares of the company’s stock, valued at approximately $1,001,000.

Several other institutional investors have also added to or reduced their stakes in KRYS. Silvant Capital Management LLC purchased a new stake in shares of Krystal Biotech during the second quarter worth about $30,000. Greenline Wealth Management LLC purchased a new stake in Krystal Biotech in the 4th quarter worth approximately $34,000. Western Wealth Management LLC bought a new stake in shares of Krystal Biotech in the 1st quarter worth approximately $34,000. Danske Bank A S purchased a new position in shares of Krystal Biotech during the third quarter valued at approximately $35,000. Finally, UMB Bank n.a. raised its holdings in shares of Krystal Biotech by 34.6% during the fourth quarter. UMB Bank n.a. now owns 144 shares of the company’s stock valued at $36,000 after acquiring an additional 37 shares in the last quarter. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Krystal Biotech Trading Down 0.6%

Krystal Biotech stock opened at $357.46 on Friday. The business’s fifty day simple moving average is $348.57 and its two-hundred day simple moving average is $303.83. Krystal Biotech, Inc. has a 12 month low of $136.73 and a 12 month high of $382.54. The company has a market capitalization of $10.58 billion, a price-to-earnings ratio of 44.79 and a beta of 0.53.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings results on Monday, August 3rd. The company reported $1.79 earnings per share for the quarter, beating the consensus estimate of $1.70 by $0.09. The firm had revenue of $119.22 million during the quarter, compared to the consensus estimate of $120.93 million. Krystal Biotech had a return on equity of 19.34% and a net margin of 54.82%. On average, equities research analysts predict that Krystal Biotech, Inc. will post 7.68 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. Royal Bank Of Canada assumed coverage on shares of Krystal Biotech in a research report on Friday, August 14th. They set an “outperform” rating and a $400.00 price objective on the stock. Bank of America increased their price target on shares of Krystal Biotech from $364.00 to $396.00 and gave the stock a “buy” rating in a research note on Tuesday, July 14th. Weiss Ratings cut Krystal Biotech from a “buy (b)” rating to a “buy (b-)” rating in a research report on Tuesday, August 18th. Wall Street Zen lowered Krystal Biotech from a “buy” rating to a “hold” rating in a research report on Saturday, June 20th. Finally, HC Wainwright lifted their price target on Krystal Biotech from $310.00 to $361.00 and gave the company a “buy” rating in a research report on Tuesday, June 16th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $365.40.

Insider Transactions at Krystal Biotech

In other news, EVP John Charles Thomas sold 1,000 shares of the stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $347.27, for a total transaction of $347,270.00. Following the sale, the executive vice president owned 1,000 shares in the company, valued at $347,270. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $308.11, for a total transaction of $7,702,750.00. Following the completion of the transaction, the insider owned 1,378,155 shares of the company’s stock, valued at approximately $424,623,337.05. The trade was a 1.78% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 51,000 shares of company stock worth $16,278,020. Corporate insiders own 13.10% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.